Dimeric Cereblon-Targeting Compounds for T-Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing immunotherapies for cancer face barriers that impede anti-tumor immunity, leading to limited therapeutic responses and drug resistance, necessitating new compounds that target cereblon-based mechanisms to enhance checkpoint blockade therapy.
Innovation Solution
Development of dimeric immunomodulatory drugs that target cereblon-based mechanisms, represented by specific compounds with structures like Formulae I, II, III, and IV, which can enhance T cell activation and tumor immunity by degrading cereblon protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing immunotherapies are used for cancer treatment, then therapeutic responses are limited, but developing new compounds increases device complexity and development time
Solution Approach 1:
The patent divides the immunotherapy approach into segmented components by developing dimeric compounds consisting of two separate immunomodulatory drug molecules linked together. This segmentation allows each component to maintain its individual cereblon-targeting function while the dimeric structure provides enhanced therapeutic efficacy through cooperative binding and improved pharmacokinetic properties
Solution Approach 2:
The patent creates composite therapeutic agents by chemically linking two immunomodulatory drug molecules (such as lenalidomide or pomalidomide units) to form dimeric structures. These composite compounds combine the cereblon-binding capabilities of individual units while introducing new pharmacological properties that overcome limitations of monomeric immunotherapies
2Reliability
If existing immunotherapies are used, then drug resistance develops, but new compound development increases manufacturing complexity
Solution Approach 1:
The dimeric compound structure is designed with separable functional units that can be synthesized independently and then linked through established chemical conjugation methods. This segmented approach to molecular design allows for modular synthesis where variations in the linking moiety or spacer arms can be made without redesigning the entire molecule, facilitating easier manufacturing and scale-up
Solution Approach 2:
The patent systematically varies parameters such as the type of linker (cleavable vs. non-cleavable), linker length, and spacer arm composition to optimize the dimeric compounds' pharmacological properties. These parameter changes allow for high-throughput screening and optimization during development while maintaining a consistent core structure that simplifies manufacturing processes
Data Source
AI summary
Disclosed are small molecules against cereblon to enhance effector T cell function. Methodos of making thes molecules and methods of using them to treat various disease states are also disclosed.